Literature DB >> 32628593

Nitrogen-Containing Heterocycles as Anticancer Agents: An Overview.

Damanpreet K Lang1, Rajwinder Kaur1, Rashmi Arora1, Balraj Saini1, Sandeep Arora1.   

Abstract

BACKGROUND: Cancer is spreading all over the world, and it is becoming the leading cause of major deaths. Today's most difficult task for every researcher is to invent a new drug that can treat cancer with minimal side effects. Many factors, including pollution, modern lifestyle and food habits, exposure to oncogenic agents or radiations, enhanced industrialization, etc. can cause cancer. Treatment of cancer is done by various methods that include chemotherapy, radiotherapy, surgery and immunotherapy in combination or singly along with kinase inhibitors. Most of the anti-cancer drugs use the concept of kinase inhibition.
OBJECTIVE: The number of drugs being used in chemotherapy has heterocycles as their basic structure in spite of various side effects. Medicinal chemists are focusing on nitrogen-containing heterocyclic compounds like pyrrole, pyrrolidine, pyridine, imidazole, pyrimidines, pyrazole, indole, quinoline, oxadiazole, azole, benzimidazole, etc. as the key building blocks to develop active biological compounds. The aim of this study is to attempt to compile a dataset of nitrogen-containing heterocyclic anti-cancer drugs.
METHODS: We adopted a structural search on notorious journal publication websites and electronic databases such as Bentham Science, Science Direct, PubMed, Scopus, USFDA, etc. for the collection of peer-reviewed research and review articles for the present review. The quality papers were retrieved, studied, categorized into different sections, analyzed and used for article writing.
CONCLUSION: As per FDA databases, nitrogen-based heterocycles in the drug design are almost 60% of unique small-molecule drugs. Some of the nitrogen-containing heterocyclic anti-cancer drugs are Axitinib, Bosutinib, Cediranib, Dasatanib (Sprycel®), Erlotinib (Tarceva®), Gefitinib (Iressa®), Imatinib (Gleevec®), Lapatinib (Tykerb ®), Linifanib, Sorafenib (Nexavar®), Sunitinib (Sutent®), Tivozanib, etc. In the present review, we shall focus on the overview of nitrogen-containing heterocyclic active compounds as anti-cancer agents. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Anti-cancer; FDA approved drugs; ayvakit; copiktra; erleada; lorbrena; nitrogen heterocycles; tazverik

Mesh:

Substances:

Year:  2020        PMID: 32628593     DOI: 10.2174/1871520620666200705214917

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  9 in total

Review 1.  Recent Applications of the Multicomponent Synthesis for Bioactive Pyrazole Derivatives.

Authors:  Diana Becerra; Rodrigo Abonia; Juan-Carlos Castillo
Journal:  Molecules       Date:  2022-07-23       Impact factor: 4.927

2.  Triclabendazole Induces Pyroptosis by Activating Caspase-3 to Cleave GSDME in Breast Cancer Cells.

Authors:  Liang Yan; Yi Liu; Xue-Feng Ma; Dan Hou; Yu-Hui Zhang; Yong Sun; Shan-Shan Shi; Tim Forouzanfar; Hai-Yan Lin; Jun Fan; Gang Wu
Journal:  Front Pharmacol       Date:  2021-07-08       Impact factor: 5.810

3.  Synthesis, Cytotoxicity and Anti-Proliferative Activity Against AGS Cells of New 3(2H)-Pyridazinone Derivatives Endowed with a Piperazinyl Linker.

Authors:  Mehmet Abdullah Alagöz; Zeynep Özdemir; Mehtap Uysal; Simone Carradori; Marialucia Gallorini; Alessia Ricci; Susi Zara; Bijo Mathew
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-25

Review 4.  Therapeutic potential of pyrrole and pyrrolidine analogs: an update.

Authors:  N Jeelan Basha; S M Basavarajaiah; K Shyamsunder
Journal:  Mol Divers       Date:  2022-01-25       Impact factor: 3.364

5.  Novel chalcone-derived pyrazoles as potential therapeutic agents for the treatment of non-small cell lung cancer.

Authors:  Natalia Maciejewska; Mateusz Olszewski; Jakub Jurasz; Marcin Serocki; Maria Dzierzynska; Katarzyna Cekala; Ewa Wieczerzak; Maciej Baginski
Journal:  Sci Rep       Date:  2022-03-08       Impact factor: 4.379

6.  Synthesis, characterization, in silico molecular docking, and antibacterial activities of some new nitrogen-heterocyclic analogues based on a p-phenolic unit.

Authors:  Abdel Haleem M Hussein; Abu-Bakr A El-Adasy; Ahmed M El-Saghier; M Olish; Aboubakr H Abdelmonsef
Journal:  RSC Adv       Date:  2022-04-26       Impact factor: 4.036

Review 7.  An Overview of the Biological Evaluation of Selected Nitrogen-Containing Heterocycle Medicinal Chemistry Compounds.

Authors:  Oluwakemi Ebenezer; Maryam Amra Jordaan; Gea Carena; Tommaso Bono; Michael Shapi; Jack A Tuszynski
Journal:  Int J Mol Sci       Date:  2022-07-23       Impact factor: 6.208

8.  Spirooxindol-1,3-oxazine Alkaloids: Highly Potent and Selective Antitumor Agents Evolved from Iterative Structure Optimization.

Authors:  Annika Eichhorst; Malte Gallhof; Alice Voss; Anett Sekora; Leon Eggers; Le Thi Huyen; Christian Junghanss; Hugo Murua Escobar; Malte Brasholz
Journal:  ChemMedChem       Date:  2022-05-23       Impact factor: 3.540

9.  Synthesis and Anticancer Evaluation of New 1,3,4-Oxadiazole Derivatives.

Authors:  Camelia Elena Stecoza; George Mihai Nitulescu; Constantin Draghici; Miron Teodor Caproiu; Octavian Tudorel Olaru; Marinela Bostan; Mirela Mihaila
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.